Skip to Content
Merck
CN
  • Beta adrenergic receptor activation inhibits oral cancer migration and invasiveness.

Beta adrenergic receptor activation inhibits oral cancer migration and invasiveness.

Archives of oral biology (2020-08-18)
Diego Mauricio Bravo-Calderón, Agnes Assao, Natália Galvão Garcia, Cláudia Malheiros Coutinho-Camillo, Martin Roffé, Janaína Naiara Germano, Denise Tostes Oliveira
ABSTRACT

The aim of this study was to verify β2-AR expression in oral squamous cell carcinoma cell lines (SCC-9 and SCC-25), and to investigate the role of this receptor in migration and invasion of these neoplastic cells. SCC-9 and SCC-25 cells were investigated for gene and protein expression of β2-AR. Cell migration and invasion were analyzed by wound healing assay and transwell invasion camera system. Different concentrations (0.1, 1 and 10 μM) of norepinephrine were used to stimulate, and 1 μM propranolol was used to block the beta-adrenergic receptors on cancer cells. Differences in median values of SCC-9 and SCC-25 and β2-AR protein expression were analyzed by Friedman test and in case of significant differences; pairwise comparisons were performed using Bonferroni correction. The results showed that the β2-AR gene and protein expression were observed in both oral cancer cell lines. The concentration of 10 μM of norepinephrine significantly inhibited (p ≤ 0.05) migration of SCC-9 and SCC-25 cell lines. Furthermore, there was a significant reduction (p ≤ 0.05) in the effect of norepinephrine on cell migration when the β2-AR was inhibited by propranolol. The blockade by propranolol showed a tendency to reverse the effect of norepinephrine on the invasiveness of SCC-9 and SCC-25. The use of beta-adrenergic receptor agonists could become an adjuvant therapeutic target in the treatment of this malignancy.